John R. Stanley

faculty photo
Professor of Dermatology
Department: Dermatology

Contact information
University of Pennsylvania School of Medicine
Department of Dermatology
421 Curie Boulevard, 1008 Biomedical Research Building
Philadelphia, PA 19104
Office: 215-898-0166
Fax: 215-573-2033
Education:
B.A. (Physics)
Cornell University, 1970.
M.D.
Harvard Medical School, 1974.
Permanent link
 

Description of Itmat Expertise

My laboratory is interested in two main areas:
1) The pathophysiology of autoimmune blistering skin diseases (e.g. pemphigus and pemphigoid). We are now characterizing the autoantibody response by cloning monoclonal antibodies from pemphigus patients, allowing us to genetically characterize pathogenic and non-pathogenic antibodies. These antibodies are being used to study the pathophysiology of disease and to screen for new targeted therapy for these diseases.
2) Development of a targeted drug delivery system. In cloning monoclonal antibodies from pemphigus patients, we found that most bound epidermis but caused no pathology. These cloned antibodies are simple single chain variable fragments, 25 kD molecules in which the variable heavy and light chain are joined by a small linker to fold into an active antigen combining site. We think that such molecules could be useful for drug delivery to the epidermis.

Selected Publications

Toumi A, Saleh MA, Yamagami J, Abida O, Kallel M, Masmoudi A, Makni S, Turki H, Hachiya T, Kuroda K, Stanley JR, Masmoudi H, Amagai M: Autoimmune reactivity against precursor form of desmoglein 1 in healthy Tunisians in the area of endemic pemphigus foliaceus. J Dermatol Sci doi: 10.1016/j.jdermsci.2013.02.002. Epub 2012 Feb 19, 70(1): 19-25 April 2013.

Kouno K, Lin C, Schechter N, Siegel D, Yang X, Seykora JT, Stanley JR: Targeted delivery of tumor necrosis factor-related apoptosis-inducing ligand to keratinocytes with a pemphigus monoclonal antibody. J Invest Dermatol February 2013 Notes: Advance online publication 4 April 2013; doi: 10.1038/jid.2013.85.

Lunardon L, Tsai KJ, Propert KJ, Fett N, Stanley JR, Werth VP, Tsai DE, Payne AS: Adjuvant rituximab therapy of pemphigus: A single center experience with 31 patients. Arch Dermatol 148: 1031-1036, 2012.

Yamagami J, Payne AS, Kacir S, Ishii K, Siegel DL, Stanley JR: Homologous regions of heavy chain complementarity determining region 3 (H-CDR3) of pemphigus antibodies cause pathogenicity. J Clin Invest 120: 4111-4117, 2010.

Yamagami J, Kacir S, Ishii K, Payne AS, Siegel DL, Stanley JR: Antibodies to the desmoglein 1 precursor proprotein but not to the mature cell surface protein cloned from individuals without pemphigus. J Immunol 183(9): 5615-5621. doi: 10.4049/jimmunol.0901691. November 2009.

Yamagami J, Kacir S, Ishii K, Payne AS, Siegel DL, Stanley JR: Antibodies to the desmoglein 1 precursor proprotein but not to the mature cell surface protein cloned from individuals without pemphigus. J Immunol 183: 5615-5621, 2009.

Yokouchi M, Saleh MA, Kuroda K, Hachiya T, Stanley JR, Amagai M, Ishii K: Pathogenic epitopes of autoantibodies in pemphigus reside in the amino-terminal adhesive region of desmogleins which are unmasked by proteolytic processing of prosequence. J Invest Dermatol 129: 2156-2166, 2009.

Ishii K, Lin C, Siegel DL, Stanley JR: Isolation of pathogenic monoclonal anti-desmoglein 1 human antibodies by phage display of pemphigus foliaceus autoantibodies. J Invest Dermatol 128: 939-948, 2008.

Payne AS, Siegel DL, Stanley JR: Targeting pemphigus autoantibodies by their heavy chain variable region genes. J Invest Dermatol 127: 1681-1691, 2007.

Heng A, Nwaneshiudu A, Hashimoto T, Amagai M, Stanley JR: Intraepidermal neutrophilic IgA/IgG anti-desmocollin 1 pemphigus. Br J Dermatol 154: 1018-1019, 2006.

back to top
Last updated: 07/26/2013
The Trustees of the University of Pennsylvania